Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Advanced BioMatrix has acquired the HyStem® line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan.
As the J.P. Morgan Healthcare Conference enters its final day for 2020, a few topics have risen to the top.
The FY20 Defense Appropriations Act provides funding to the Department of Defense Peer Reviewed Medical Research Program to support medical research projects of clear scientific merit and direct relevance to military health.
Xyall BV has been identified as a next-generation global innovator in molecular pathology, winning Series A seed investment of €5 million from investment partners Sioux Technologies, BOM Brabant Ventures, the Netherlands Enterprise Agency and other private investors.
Novo Seeds, the early stage investment and company creation team of Novo Holdings, publishes its review of 2019 - a year of significant progress and growth.
NBE-Therapeutics AG announces the closing of a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders.
On 6 December 2019, Recipharm AB, through its directly wholly-owned subsidiary Recipharm Holdings Limited, published an offer document setting out the full terms and conditions of its recommended cash offer to acquire the entire issued and to be issued share capital of Consort Medical plc.
Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system
What’s New at the J.P. Morgan Life Healthcare Conference?
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.